On December 2, 2015, Ascletis Pharma Inc. closed the transaction. The company amended and received $55 million in the series A round. The company received $20 million in second tranche of series A round from a lead new investor, Goldman Sachs Group, Merchant Banking Division.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.42 HKD | +1.43% | +4.41% | -2.74% |
04-03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
04-03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.74% | 181M | |
-3.79% | 87.06B | |
+1.45% | 40.25B | |
-15.86% | 31.09B | |
+52.66% | 24.74B | |
-14.47% | 15.91B | |
-9.12% | 11.96B | |
-14.38% | 11.92B | |
-42.56% | 11.61B | |
+4.87% | 8.73B |
- Stock Market
- Equities
- 1672 Stock
- News Ascletis Pharma Inc.
- Ascletis Pharma Inc. announced that it has received $55 million in funding from Tasly Pharmaceutical Group Co., Ltd, Pavilion Capital Pte. Ltd., CBC Group, West Street Capital Partners